Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Viatris Inc.
  6. News
  7. Summary
    VTRS   US92556V1061

VIATRIS INC.

(VTRS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Viatris : Former Mylan executive pleads guilty to insider trading

09/17/2021 | 05:32pm EST
Logo of Mylan Laboratories, a company primarily engaged in the commercialization of generic drugs is pictured in Merignac near Bordeaux

(Reuters) - A former information technology executive at Mylan pleaded guilty on Friday to insider trading for using tips from the drugmaker's chief information officer to trade in its stock, generating $4.27 million of illegal profit, authorities said.

Dayakar Mallu, 51, admitted to conspiring to commit securities fraud, and to an unrelated charge of helping prepare a false tax return, before U.S. District Judge W. Scott Hardy in Pittsburgh.

Mylan is now known as Viatris Inc after merging last November with Pfizer Inc's Upjohn off-patent drug business, which Pfizer spun off. The combined company's headquarters remain in Canonsburg, Pennsylvania, a Pittsburgh suburb.

Authorities said that between October 2017 and July 2019, Mallu traded Mylan stock based on material nonpublic information about the company's results, U.S. Food and Drug Administration drug approvals, and the Upjohn merger.

Mallu, now a resident of Orlando, Florida, was previously vice president of global operations information technology at Mylan, and had been a friend and colleague of the chief information officer, court records show.

The tax return charge related to a computer programming company based in Farmington Hills, Michigan, that Mallu owned, prosecutors said.

Mallu could face 57 to 71 months in prison under recommended federal guidelines at his Jan. 24, 2022, sentencing, according to a plea agreement with the U.S. Department of Justice.

He also agreed to forfeit $4.27 million and make restitution to the Internal Revenue Service, court records show. The U.S. Securities and Exchange Commission filed related civil charges.

Aitan Goelman, a lawyer for Mallu, declined to comment.

Ramkumar Rayapureddy, who was Mylan's CIO at the time of Mallu's trading, now holds the same job at Viatris, according to Viatris' website and his LinkedIn Page.

The SEC said Mallu shared some profits with the source of his inside information, who directed him to make cash payments in person, in India, to avoid detection.

Rayapureddy did not immediately respond to a request for comment.

In a statement, Viatris said: "The company is committed to the highest standards of integrity and compliance with the law. The company has been fully cooperating with the authorities. We are not in a position to comment further."

(Reporting by Jonathan Stempel in New York and Chris Prentice in Washington; editing by Jonathan Oatis)

By Jonathan Stempel and Chris Prentice


ę Reuters 2021
All news about VIATRIS INC.
11/22Walgreens Prescription Savings Club Offers Steep Savings on Viatris' Long-Acting Insuli..
AQ
11/22VIATRIS INC. : Ex-dividend day for
FA
11/18Biocon to Offer Insulin Glargine Injection Through Walgreens Prescription Savings Club
MT
11/18Endo International Unit Start Shipment Of Generic Calcitonin Salmon Injection
MT
11/18Viatris to Participate in Evercore ISI 4th Annual HealthCONx Conference
PR
11/17Biocon Biologics and Viatris Announce Launch of Interchangeable SEMGLEE (insulin glargi..
AQ
11/16Biocon Biologics Launches Insulin Glargine Injections in US
MT
11/16Viatris and Biocon Biologics Announce Launch of Interchangeable SEMGLEE« (insulin glarg..
PR
11/11Viatris Donates $1 Million as Founding Champion to New Orleans-based SBP's "Got Your Ba..
PR
11/10Federal Circuit Reaffirms Valeant Hatch-Waxman Venue Ruling
AQ
More news
Analyst Recommendations on VIATRIS INC.
More recommendations
Financials (USD)
Sales 2021 17 864 M - -
Net income 2021 -952 M - -
Net Debt 2021 21 880 M - -
P/E ratio 2021 -16,6x
Yield 2021 2,57%
Capitalization 15 420 M 15 420 M -
EV / Sales 2021 2,09x
EV / Sales 2022 1,97x
Nbr of Employees 38 000
Free-Float 99,7%
Chart VIATRIS INC.
Duration : Period :
Viatris Inc. Technical Analysis Chart | VTRS | US92556V1061 | MarketScreener
Technical analysis trends VIATRIS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 12,75 $
Average target price 19,50 $
Spread / Average Target 52,9%
EPS Revisions
Managers and Directors
Michael Goettler Chief Executive Officer & Director
Rajiv Malik President & Director
Sanjeev Narula Chief Financial Officer
Robert J. Coury Executive Chairman
Ramkumar V. Rayapureddy Chief Information Officer
Sector and Competitors
1st jan.Capi. (M$)
VIATRIS INC.-31.96%15 420
JOHNSON & JOHNSON1.16%419 109
ROCHE HOLDING AG16.05%336 162
PFIZER, INC.46.70%303 095
NOVO NORDISK A/S67.00%247 254
ELI LILLY AND COMPANY54.21%236 049